More than $200 million in partnership with Pfizer/Dewpoint to develop potential DM1 therapies

On January 6, Dewpoint announced a new research collaboration with Pfizer to develop a potential treatment for severe muscular dystrophy Type 1 (DM1).
Under the agreement, Dewpoint will receive an advance payment and will be eligible for research and development and sales milestone payments, and if all milestones are achieved, the company will receive payments totalling up to $239 million and will be eligible for any approved pharmaceutical royalties.
, DM1 is a rare genetic disorder, one of two types of myotrophic dystrophy, and a genetic disorder linked to the DMPK gene.
diagnosed with DM1 experience muscle atrophy and weakness, dyslea, cataracts, heart disease, intellectual disability and early death.
there is currently no cure for DM1 to address its root cause.
biotechnology companies in the United States and Germany are working on condensed matter, a new area of research that could help explain some aspects of cell biology that remain mysterious to researchers.
if you look back at biology textbooks, it almost certainly points out that the principle of human cells is membranes.
now, the cohesion of biom molecules, a transient droplet of proteins and RNA, is being used by Dewpoint to find new ways to discover drugs.
Dewpoint, biometric condensation is formed through a process called phase separation, a membrane-free droplet in a cell that promotes molecular interactions and helps cells perform important functions.
has been shown to play a key role in critical biological processes and serious incurable diseases, including neurodegenerative changes, cancer, inflammation, infectious diseases, metabolic diseases and rare genetic diseases.
first condensates were observed more than 100 years ago.
, however, until the molecular cohesion function is discovered, it is not known how the right molecules can find each other at the right time to catalyce important processes in a cellularly crowded molecular environment.
it was only more than a decade ago that scientists, including Newpoint founder Tony Hyman of the Max Planck Institute in Germany and Rick Young of the Whitehead Institute, began to understand the dynamic properties and functions of condensed matter.
Dewpoint developed drugs that use this biology.
this technology is clearly sought after.
In 2019, Dewpoint signed a $100 million agreement with Bayer to address two neglected areas, heart disease and women's health, and in the same year, a $305 million agreement with Mercedon to use its technology to treat AIDS.
fall of 2019, Dewpoint also received $77 million in round B financing, highlighting the growing market value of its technology, which is favored by the outside world.
source: 1.Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy 2.Pfizer taps Dewpoint Therapeutics in $239M dystrophy drug deal